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Abstract
Background
Since 2004, Médecins Sans Frontières-Switzerland has provided treatment and care for
people living with HIV in Dawei, Myanmar. Renal function is routinely monitored in patients
on tenofovir (TDF)-based antiretroviral treatment (ART), and this provides an opportunity to
measure incidence and risk factors for renal dysfunction.
Methods
We used routinely collected program data on all patients aged15 years starting first-line
TDF-based ART between January 2012 and December 2013. Creatinine clearance (CrCl)
was assessed at base line and six-monthly, with renal dysfunction defined as CrCl < 50ml/
min/1.73m2. We calculated incidence of renal dysfunction and used Cox regression analy-
sis to identify associated risk factors.
Results
There were 1391 patients, of whom 1372 had normal renal function at baseline. Of these,
86 (6.3%) developed renal dysfunction during a median time of follow-up 1.14 years with an
incidence rate of 5.4 per 100 person-years: 78 had CrCl between 30–50ml/min/1.73m2 and
were maintained on TDF–based ART, but 5 were changed to another regimen: 4 because
of CrCl <30ml/min/1.73m2. Risk factors for renal dysfunction included age45 years, diag-
nosed diabetes, underlying renal disease, underweight and CD4 count <200cells/mm3.
There were 19 patients with baseline renal dysfunction and all continued on TDF-based
PLOSONE | DOI:10.1371/journal.pone.0135188 August 24, 2015 1 / 11
OPEN ACCESS
Citation: Kyaw NTT, Harries AD, Chinnakali P,
Antierens A, Soe KP, Woodman M, et al. (2015) Low
Incidence of Renal Dysfunction among HIV-Infected
Patients on a Tenofovir-Based First Line Antiretroviral
Treatment Regimen in Myanmar. PLoS ONE 10(8):
e0135188. doi:10.1371/journal.pone.0135188
Editor: Dimitrios Paraskevis, University of Athens,
Medical School, GREECE
Received: March 10, 2015
Accepted: July 19, 2015
Published: August 24, 2015
Copyright: © 2015 Kyaw et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: A raw data set is
available as a Supporting Information file.
Funding: The programme was funded by The Union,
MSF, The Department for International Development
(DFID), UK and the World Health Organization. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
ART: CrCl stayed between 30–49 ml/min/1.73m2 in five patients while the remainder
regained normal renal function.
Conclusions
In a resource-poor country like Myanmar, the low incidence of renal toxicity in our patient
cohort suggests that routine assessment of CrCl may not be needed and could be targeted
to high risk groups if resources permit.
Introduction
HIV/AIDS has been transformed from a short-lived fatal disease to a chronic manageable dis-
ease through the use of antiretroviral therapy (ART), and the life expectancy of people living
with HIV (PLHIV) on ART approaches that of the general population[1,2].By 2013, globally
there were an estimated 12.9 million PLHIV on ART and 1.1 million lived in South East Asian
countries [3].In 2010, the World Health Organization (WHO) recommended the use of better
and safer first line ART regimens which include Tenofovir (TDF) and zidovudine (AZT) to
avoid the severe and often irreversible side effects caused by stavudine (d4T)- based therapy
[4].In the most recent 2013 Consolidated ART guidelines there is furthermore a strong recom-
mendation to phase out d4T in favour of TDF as the latter drug is much better tolerated, has a
low frequency of adverse events and can be taken daily allowing a once-a-day fixed-dose com-
bination of tenofovir-lamivudine-efavirenz for treatment[5].
While TDF is well accepted by physicians and patients, one principal concern is renal toxic-
ity. A systematic review and meta-analysis of 17 studies indicated that TDF was associated with
a greater loss of kidney function (as measured by creatinine clearance) and a greater risk of
acute renal failure compared with control subjects [6]. However, these effects are thought to be
modest, and do not preclude the use of TDF in resource-poor areas where monitoring of renal
function is not feasible. WHO recommends the need for further research in this area to better
understand first, the magnitude of long-term toxicity, and second, whether there are any pre-
existing factors for the development of renal dysfunction such as age, hypertension, diabetes
and concomitant use of potentially nephrotoxic drugs [5].This information will be helpful in
determining whether laboratory screening and monitoring of renal function in resource-poor
settings should be routine or undertaken only in targeted high risk groups.
Since 2004, Médecins Sans Frontières-Switzerland (MSF-CH) has provided treatment and care
for a large cohort of PLHIV in Dawei District in southern Myanmar. Since January 2012, all new
patients received a TDF-based ART as a preferred first-line regimen, and since June 2013,in line
withWHO guidelines [5],all patients who were previously on a d4T-based regimen have been
changed to a TDF-based regimen. All these patients were tested for virological failure by perform-
ing viral load tests before switching.As part of routine care for patients on TDF, renal function is
monitored by assessing creatinine clearance (CrCl)at base line and regularly during follow-up.
This MSF project in Myanmar provides an opportunity to measure incidence and risk fac-
tors for renal dysfunction in a real world setting in a large cohort of PLHIV on TDF-based
ART with serial serum creatinine measurements and CrCl calculations. There are no data in
Myanmar on renal dysfunction in PLHIV receiving TDF, so this information will be of value
for HIV/AIDS programme management in determining whether renal function monitoring
should be recommended in all sites in the country providing TDF-based ART. The aim of this
study therefore was to determine the incidence and risk factors for renal dysfunction in PLHIV
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started on TDF-based ART between January 2012 and December 2013 in Dawei District,
Myanmar. Specific objectives were to report on:- i) demographic, clinical and immunological
baseline characteristics; ii) the incidence of renal dysfunction after starting TDF in patients
with normal renal function at baseline, and their associated risk factors and outcomes; and iii)
outcomes of patients with renal dysfunction at baseline.
Methods
Study design
This was a retrospective cohort analysis of PLHIV who started TDF-based first-line ART regimen
Study setting
HIV treatment and care in Myanmar. Myanmar is located in Southeast Asia with an esti-
mated population of 51.4 million, of whom 60% live in rural areas [7].Administratively, the
country is divided into 14 states/regions, 65 districts and 325 townships. In 2012, the overall
HIV prevalence was 0.5%, with higher prevalence in key populations-6% in female sex workers,
7% in men who have sex with men and 17% in injecting drug users [8].National ART scale up
started in 2010, and by the end of 2013, over 67,000 people were on ART[9].
The criteria for starting ART in PLHIV are CD4 count less than 350copies/ml or WHO clin-
ical stage 3 or 4, in line with the WHO 2010 Guidelines [4].An estimated 40% of PLHIV are
provided with ART through the public sector under the National AIDS Program (NAP), and
the remainder is provided by private clinics, and international and local non-governmental
organizations. Before 2010, d4T-based ART was the most commonly used first line ART regi-
men in the country. The National Guidelines for ART in 2010 recommended either AZT-
based or TDF-based ART regimen as preferred first line regimen to avoid the adverse effects of
d4T[10]. The National Guidelines also recommended screening of PLHIV on TDF for renal
dysfunction by assessing CrCl. However the implementation of renal function monitoring is
sub-optimal in the country due to lack of resources, and there are no specific recommendations
on timing or frequency of conducting tests.
HIV treatment and care in MSF project. MSF-CH HIV care and treatment clinic is
located in Dawei District, Tanintharyi region in southern part of Myanmar since 2004. Patients
receiving care and treatment in this clinic are from Tanintharyi regions and nearby states. In
the MSF-CH clinic, there were over 3000 patients who were on first line and second line ART
by the end of 2013, treated according to the national protocol. About 50% of patients on first
line ART were on TDF-based regimen and the rest of the patients were on AZT, d4T or Abaca-
vir-based regimens. Baseline CrCl is measured in all patients about to start TDF-based ART.
TDF is initiated for those with baseline CrCl50ml/min/1.73m2.Those with CrCl<50ml/min/
1.73m2 are supposed to start on non-TDF-based ART, although exceptions are made by clini-
cians. PLHIV are also screened for diabetes, hypertension, and hepatitis B(with the use of the
Determine HBsAg test, Alere Medical Co., Ltd., Chiba, Japan) and hepatitis C (with the use of
the OraQuick HCV Rapid Antibody Test, OraSure Technologies, Inc., Pennsylvania, USA);
and information on use of nephrotoxic drugs and underlying renal disease (from patient rec-
ords or previous abnormal renal function tests) is also recorded. Diabetes is diagnosed if the
Random Plasma Glucose is> 11.1mmol/l or Fasting Plasma Glucoseis> 7.0 mmol/l. Hyper-
tension is diagnosed if the systolic blood pressure is160 mmHg and/or diastolic blood pres-
sure is90 mmHg at two visits within three months. The drugs used to manage hypertension
include hydrochlorothiazide, enalapril, amlodipine and atenolol while those used to manage
diabetes include metformin and glibenclamide.
Renal Dysfunction with Use of Tenofovir
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After starting TDF, CrCl is calculated at 6-monthly intervals. Patients with baseline risk fac-
tors such as chronic renal disease, diabetes, hypertension, hepatitis B and hepatitis C are
screened at 1 month and 3 months after initiation, then every six months. All treatment and
laboratory investigations are provided free of cost.
Definition for renal dysfunction. We defined renal dysfunction as CrCl less than 50 ml/
min/1.73m2 and severe renal dysfunction as CrCl less than 30 ml/min/1.73m2.Serum creatinine
measurements were performed at the clinic laboratory using rapid test (StatSensor, Nova Bio-
medical Corporation, Massachusetts, USA), and CrCl is calculated by using the Crockcroft-
Gault formula recommended by WHO[5].
Study population
All adults (aged 15 years or above) with HIV infection who started on first-line TDF-based
ART between January 2012 and December 2013and followed for a period of at least 6 months
were included in the study.
Data variables
Data variables included: age, sex, previous ART exposure, ART start date, other medication
(at start and during ART), co-morbidities (at start and during ART), results of hepatitis B
and C testing, height, weight, WHO clinical stage, CD4 cell count, CrCl (at start and during
ART along with the date) and patient outcomes. These data were collected from an electronic
FUCHIA database(Follow Up and Care for HIV Infection and AIDS)(2010 Epicentre, http://
www.epicentre.msf.org) and from patient medical files. The electronic database and patient
medical files do not include patient names but patient numbers.
Analysis and statistics
Data were single entered and analysed for frequencies and proportions in EpiDataversion 3.1
for data entry, and version 2.2.2.182 for analysis [11].The records were anonymized and de-
identified prior to analysis.Data were censored on July 1, 2014. Death and loss to follow up
patients were also censored and this was taken account of in the Kaplan Meier plots. In PLHIV
with normal renal function at baseline, time to event analysis was carried out using STATA
version 12.1and a Kaplan Meier plot used to estimate cumulative incidence of renal dysfunc-
tion. Unadjusted Cox proportional hazard ratios were calculated to assess the possible associa-
tion of characteristics with the development of renal dysfunction. Characteristics at a threshold
P value of<0.2 in the univariate analysis were included in the multivariate Cox regression
model and adjusted hazard ratios with 95% confidence intervals were calculated. A P-value of
less than 0.05 was considered statistically significant.
Ethics
The study was approved by the Ethics Advisory Group of the International Union Against
Tuberculosis and Lung Disease, Paris, France, and the Ethical Review Committee of the
Department of Medical Research (Lower Myanmar). As the study only involved a review of
patient records, the need for informed patient consent was waived.
Results
There were 1391 HIV-infected patients started on a first-line TDF-based ART regimen during
the study period and the median duration (IQR) of follow up was 1.14 (0.78–1.6) years. Their
median (interquartile range) age was 38(33–42) years. Demographic, clinical and
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immunological baseline characteristics are shown in Table 1. 58% of patients had previously
been on other ART regimens, either D4T-based (N = 749, 54%) or AZT-based ART (N = 56,
4%). Over 90% of patients were taking concomitant cotrimoxazole preventive therapy. Less
than 10% had additional co-morbidities such as diabetes, hypertension or pre-existing renal
disease. Of those tested for Hepatitis B and Hepatitis C, 11% and 16% respectively were posi-
tive. 20% of patients were underweight (BMI<18.5). In terms of immune suppression, 83% of
patients were in WHO Clinical Stage 3 or 4 and 32% had a CD4 cell count<200/mm3. There
were 19 (1.3%) patients who had renal dysfunction at the start of TDF-based ART, all of whom
had a CrCl between 30 and 49 ml/min/1.73m2. During follow-up, few patients were newly
diagnosed with diabetes or hypertension during ART, and 3% were given potentially nephro-
toxic drugs (see Table 2).
Table 1. Baseline characteristics of HIV-infected patients started on tenofovir-based antiretroviral therapy between January 2012 and December
2013 in Myanmar.
Baseline characteristics Number Percentage
Total All patients 1391 100
Age group in years 15–24 47 3
25–44 1090 79
45 254 18
Gender Male 566 41
Female 825 59
Medication Previous ART Exposure 805 58
Concomitant use of cotrimoxazole 1313 94
Co-morbidities Diabetes Mellitus (already known) 16 1
Hypertension (already known) 116 8
Renal disease (already known) 9 <1
Hepatitis B Tested: 1152 83
Hepatitis B surface antigen positive 132 11 a
Hepatitis C Tested: 444 32
Hepatitis C antibody positive 69 16 a
BMI (kg/m2) <16.0 57 4
16–16.9 55 4
17.0–18.4 171 12
18.5–24.9 128 9
25 and above 980 71
WHO Clinical Stage 1 70 5
2 166 12
3 719 52
4 436 31
CD4 Cells/mm3 <200 441 32
200 and above 935 67
Not recorded 15 1
Renal status (baseline) Normal renal function b 1372 99
Renal dysfunction c 19 1
BMI = body mass index; WHO = World Health Organization
a Percentage of those tested
b Creatinine clearance  50ml/min/1.73m2
c Creatinine clearance < 50ml/min/1.73m2
doi:10.1371/journal.pone.0135188.t001
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Of 1372 patients with normal baseline renal function who were followed for a total of 1632
person-years, 86 (6.3%) developed renal dysfunction, 79(5.8%) died and 39(2.8%) were lost to
follow up during the study period. The incidence rate of renal dysfunction was 5.4 per 100 per-
son-years of follow-up. The Kaplan-Meier curve shows the cumulative incidence of renal dys-
function from the time when patients started treatment with TDF. The cumulative incidence of
patients developing renal dysfunction over time was 4% at 12 month and 8% at 24 months
from the time of TDF initiation (Fig 1).Of 86 patients who developed renal dysfunction, 78
had creatinine clearance between 30–50ml/min/1.73m2 and were maintained on TDF–based
ART by the end of follow-up. Of the remainder, two patients died, one was transferred out,
four were changed to a non-TDF ART regimen due to CrCl<30ml/min/1.73m2, and one was
changed to a non-TDF containing second line regimen due to first line ART failure. Risk fac-
tors associated with the development of renal dysfunction are shown in Table 3. In the adjusted
analysis, female gender, age45 years, diabetes, renal disease, under-nutrition, CD4 count
<200cells/mm3were associated with developing renal dysfunction.
Of 19 (1%) patients who had renal dysfunction at the start of TDF-based ART, all continued
on the TDF regimen: CrCl remained between 30–49 ml/min/1.73m2 in five patients and the
remainder regained normal renal function.
Discussions
To the best of our knowledge, this is the first study in Myanmar to assess renal function in
patients starting on TDF-based ART and the incidence of renal dysfunction during follow-up.
The majority of patients had normal renal function at baseline. Just over six percent of these
patients developed renal dysfunction during follow up, which is similar to recent studies done
in Asia [12,13], but in the majority of these patients this was not severe enough to warrant a
change in therapy. Only four patients (0.3%) progressed to severe renal dysfunction needing a
change to an alternative ART regimen, with these findings mirroring those from elsewhere
[14].These overall results are in line with previous studies which concluded that the clinical
magnitude of renal toxicity during TDF-based ART is modest[6].This low incidence of renal
toxicity is further confirmed by more recent publications from Africa and Asia [15,16]although
differences in definitions of renal dysfunction and duration on TDF-based ART make it diffi-
cult to compare findings from one study to another.
We found that baseline factors such as age45 years, being female, underweight, having
underlying renal disease and diabetes, and low CD4 count were associated with the develop-
ment of renal dysfunction. These findings are similar to those of other studies. Women with
low body weight are at risk of renal toxicity due to exposure to high TDF drug concentrations
[17].Older age, comorbidities with diabetes, lower BMI and low CD4 count are also
Table 2. Diseases that were newly diagnosed or nephrotoxic drugs that were given in HIV-infected
patients with normal renal function on tenofovir-based antiretroviral therapy between January 2012
and December 2013 in Myanmar.
Events that occurred after start of ART Number Percentage
All patients 1372 100
Diabetes Mellitus 18 1.3
Hypertension 23 1.7
Use of nephrotoxic drugsa 37 3
ART = antiretroviral therapy
a included amphotericin B, amikacin, acyclovir, non-steroidal anti-inﬂammatory drugs
doi:10.1371/journal.pone.0135188.t002
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documented as risk factors in studies from Africa and Asia [18,19].However, these findings are
not consistent as one report from USA showed no association with pre-existing renal risk fac-
tors [20].
There were a few patients (1%) with pre-existing renal dysfunction who were started on
TDF that was not in accordance with protocol. Reassuringly, most of these patients regained
normal renal function during follow-up and in the remainder none progressed to severe renal
disease. HIV infection itself is a cause of renal disease[21]and our findings suggest that TDF-
based ART is an acceptable regimen for treating such patients. Improvement in renal function
in those with pre-existing renal dysfunction has previously been recorded [16,22].
The strengths of this study were the large cohort of patients registered and followed within a
routine programme setting. As a result of reasonable laboratory infrastructure, we were also
able to screen for co-morbidities such as diabetes and assess for the presence of hepatitis B and
C infection. Since the proportions of deaths and lost to follow up during study period were low,
outcomes were less likely to be affected. We used STROBE guidelines and sound ethics princi-
ples for the conduct and reporting of this observational study [23,24]. There were some limita-
tions. First, we used the Cockcroft Gault formula to calculate CrCl to estimate glomerular
filtration rate, but other serum creatinine-based estimation equation such as Modification of
Diet in Renal Disease formula was shown to have higher accuracy to estimate CrCl in HIV
infected adult [25]. Second, the main targets of TDF renal toxicity are the proximal renal
tubules but we did not assess renal tubular dysfunction because of the need for additional labo-
ratory analysis which was unavailable during the study period[26].Third, the data were col-
lected retrospectively from patient records which may have had inaccuracies.
Fig 1. Cumulative incidence of renal dysfunction in HIV-infected patients
doi:10.1371/journal.pone.0135188.g001
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This study strengthens the evidence base for the country wide management of HIV-infected
patients starting TDF-based ART. The low incidence of renal toxicity suggests that routine
Table 3. Characteristics at baseline and during treatment in HIV-infected patients with normal renal function on tenofovir-based ART who devel-
oped renal dysfunction during follow-up in Myanmar.
Characteristics Renal Dysfunction N
(%)
Rate per 100
person yrs
Unadjusted HR§(95%
CI)
P
value
Adjusted HR§(95%
CI)
P
value
Total 86(6) 5.4
Age group in years 15–24 0 - - - - -
25–44 47 (4) 3.7 Ref Ref
45 39(16) 13.9 3.8 (2.5–5.8) <0.001 3.4 (2.2–5.2) <0.001
Gender Male 38(5) 4.1 Ref Ref
Female 48(9) 7.4 1.8 (1.2–2.8) 0.01 1.8 (1.2–2.9) 0.009
Previous ART Yes 41(5) 4.3 0.6 (0.4–0.9) 0.02 1.1(0.6–1.9) 0.8
No 45(8) 7.1 Ref Ref
Use of
cotrimoxazole
Yes 44(8) 7.2 1.7 (1.1–2.6) 0.02 1.2 (0.7–1.9) 0.51
No 42 (5) 4.3 Ref Ref
Nephrotoxic drugs Yes 5(14) 12.6 2.4 (1.0–6.0) 0.10 2.1(0.8–5.4) 0.11
No 81(6) 5.2 Ref Ref
Diabetes Mellitusa Yes 7 (21) 19.1 3.8 (1.7–8.2) <0.001 3.6 (1.6–8.2) 0.002
No 79(6) 5.1 Ref Ref
Hypertensionb Yes 13(10) 8.5 1.7 (0.9–3.1) 0.08 1.4 (0.7–2.6) 0.34
No 73(6) 5.1 Ref Ref
Known Renal
Disease
Yes 3(33) 27.9 5.4 (1.7–17) 0.004 3.5 (1.1–11.4) 0.04
No 79(6) 5.1 Ref Ref
Unknown 4(17) 15.1 3 (1.1–8.1) 0.03 3.6 (1.3–10.5) 0.02
Hepatitis B Negative 67(6) 5.2 Ref
Positive 13(9) 7.2 1.4 (0.8–2.5) 0.26
Not tested 6(6) 5.1 1.0 (0.4–2.2) 0.94
Hepatitis C: Negative 26(7) 5.5 Ref
Positive 2(3) 2.1 0.4(0.1–1.6) 0.20
Not tested 58(6) 5.7 1.0 (0.7–1.6) 0.89
BMI (kg/m2): <16.0 9(16) 17.3 3.9 (1.9–7.9) <0.001 2.3 (1.1–5) 0.03
16–18.5 24(10.8) 10.0 2.3(1.4–3.7) 0.17 1.8 (1.1–3.2) 0.02
18.5–24.9 52(5.4) 4.5 Ref Ref
25 and
above
1(0.8) 0.7 0.2(0.0–1.1) 0.06 0.2(0.0–0.9)-
WHO Clinical
Stage:
1 4(6) 5.4 Ref - -
2 7(4) 3.8 0.7 (0.2–2.) 0.58 - -
3 46(6) 5.4 1.0 (0.4–2.8) 1.0 - -
4 29(7) 6.0 1.1 (0.4–3.2) 0.84 - -
CD4 Cell /cumm3 <200 43(10) 9.1 2.6 (1.7–4.0) <0.01 2.3 (1.2–4.3) 0.02
200 and
above
39(4) 3.6 Ref
Not recorded 4(27) 20.3 5.9(2.1–16.6) <0.01 1.9 (0.6–5.8) 0.32
ART = antiretroviral therapy; HR = hazard ratio; CI = conﬁdence interval; BMI = body mass index; WHO = World Health Organization
a included patients who had diagnosed diabetes mellitus before or after TDF started
b included patients who had diagnosed hypertension before or after TDF started
§Unadjusted and adjusted HR were calculated by using Cox proportional Hazard methodology
doi:10.1371/journal.pone.0135188.t003
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assessment of CrCl may not be necessary. However, care needs to be taken with certain high
risk groups such as those aged45 years and those with underlying renal disease, diabetes,
underweight and severe immune suppression, and if resources permit, they should have creati-
nine clearance measured at baseline and during follow up. Further work is needed to a) moni-
tor renal function for longer periods of time in order to assess longer term outcomes, and b)
understand the magnitude, relevance and programmatic importance of renal tubular toxicity.
In conclusion, this study on nearly 1400 HIV infected patients starting first line TDF based
ART has shown a low incidence of renal dysfunction during follow up. Patients with certain
characteristics such as age45 years, underlying renal disease, diabetes, underweight and
severe immune suppression—are at increased risk of renal dysfunction, and may require tar-
geted renal monitoring during treatment if resources permit.
Supporting Information
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